ES2033426T3 - Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina. - Google Patents

Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina.

Info

Publication number
ES2033426T3
ES2033426T3 ES198888302657T ES88302657T ES2033426T3 ES 2033426 T3 ES2033426 T3 ES 2033426T3 ES 198888302657 T ES198888302657 T ES 198888302657T ES 88302657 T ES88302657 T ES 88302657T ES 2033426 T3 ES2033426 T3 ES 2033426T3
Authority
ES
Spain
Prior art keywords
controlled release
deoxytimidine
azido
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888302657T
Other languages
English (en)
Inventor
Harry Phillip Jones
Robert Judson Mackey
Michael John Desmond Gamlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2033426T3 publication Critical patent/ES2033426T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A FORMULACIONES FARMACEUTICAS QUE COMPRENDEN UNIDADES DISCRETAS DE ZIDOVIDINA PROPORCIONADAS CON UN RECUBRIMIENTO DE LIBERACION CONTROLADO EN EL QUE DICHAS UNIDADES ESTAS PREFERIBLEMENTE EN FORMA DE ESFEROIDES.
ES198888302657T 1987-03-27 1988-03-25 Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina. Expired - Lifetime ES2033426T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878707421A GB8707421D0 (en) 1987-03-27 1987-03-27 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ES2033426T3 true ES2033426T3 (es) 1993-03-16

Family

ID=10614823

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888302657T Expired - Lifetime ES2033426T3 (es) 1987-03-27 1988-03-25 Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina.

Country Status (17)

Country Link
US (1) US4917900A (es)
EP (1) EP0284407B1 (es)
JP (1) JP2719344B2 (es)
KR (1) KR960013434B1 (es)
AT (1) ATE63818T1 (es)
AU (1) AU607474B2 (es)
CA (1) CA1308026C (es)
DE (1) DE3862974D1 (es)
DK (1) DK175348B1 (es)
ES (1) ES2033426T3 (es)
GB (1) GB8707421D0 (es)
GR (1) GR3002030T3 (es)
IE (1) IE60605B1 (es)
IL (1) IL85870A (es)
NZ (1) NZ224026A (es)
PT (1) PT87081B (es)
ZA (1) ZA882168B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051361A (en) * 1988-10-19 1991-09-24 Sigma Chemical Company AZT immunoassays, derivatives, conjugates and antibodies
US4938966A (en) * 1988-11-30 1990-07-03 Riker Laboratories, Inc. Controlled release flecainide acetate formulation
GB8912420D0 (en) 1989-05-31 1989-07-19 Schram Cornelius J Ultrasonic systems
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
DE550714T1 (de) * 1991-06-21 1995-06-14 Acic Canada Inc Antiviralverbindungen und Ihrer Verfahren zur Herstellung.
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
CA2141788C (en) * 1992-08-04 2001-12-11 James M. Dunn Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
KR20030011805A (ko) * 2000-03-30 2003-02-11 브리스톨-마이어스스퀴브컴파니 스타부딘을 함유하는 서방성 비들렛
AU2003244110A1 (en) * 2002-06-24 2004-01-06 Asahi Denka Co., Ltd. Flame retarder composition and flame retardant resin composition containing the composition
US20050287177A1 (en) * 2002-11-08 2005-12-29 Glaxo Group Unlimited And Smithkline Beecham Corp. Pharmaceutical compositions
WO2005048978A2 (en) * 2003-10-01 2005-06-02 Lupin Limited A controlled release pharmaceutical composition and a process for preparing the same
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2009010842A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
CN106333957A (zh) * 2016-08-19 2017-01-18 丁静 齐多夫定用于制备自身免疫性神经炎治疗药物的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE145365C (es) *
BE785702A (fr) * 1971-07-14 1972-10-16 Roehm Gmbh Produits de revetement de formes medicamenteuses et leur utilisation
BE787973A (fr) * 1971-09-04 1973-02-26 Beecham Group Ltd Comprimes pharmaceutiques a effet retard
ES438635A1 (es) * 1974-06-24 1977-02-16 Shinetsu Chemical Co Procedimiento para el revestimiento de moldes solidos de do-sificacion.
ATE13486T1 (de) * 1980-11-12 1985-06-15 Ciba Geigy Ag Schnellzerfallende arzneimittel-presslinge.
EP0052075A1 (de) * 1980-11-12 1982-05-19 Ciba-Geigy Ag Körnige Arzneimittel-Retardform
DE3045135A1 (de) * 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
IT1168014B (it) * 1981-08-05 1987-05-20 Erba Farmitalia Forme farmaceutiche a cessione protratta
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
JPS59227817A (ja) * 1983-06-07 1984-12-21 Toyo Jozo Co Ltd 持続性経口用ブレデニン製剤
JPH075457B2 (ja) * 1983-08-16 1995-01-25 ザ ウエルカム フアウンデ−シヨン リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
DK164392C (da) * 1985-03-16 1992-11-09 Wellcome Found Anvendelse af 3'-azido-3'-desoxythymidin til fremstilling af et laegemiddel til behandling af eller profylakse for en human retrovirusinfektion
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
EP0199451B1 (en) * 1985-03-16 1996-03-06 The Wellcome Foundation Limited Therapeutic nucleosides
GB8506869D0 (en) * 1985-03-16 1985-04-17 Wellcome Found Antiviral compound
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
IT1227336B (it) * 1987-09-11 1991-04-08 Squibb & Sons Inc Composizione farmaceutica contenente un carico elevato di medicamento e procedimento per la sua preparazione

Also Published As

Publication number Publication date
DK175348B1 (da) 2004-09-06
KR880010759A (ko) 1988-10-24
IE880899L (en) 1988-09-27
EP0284407A2 (en) 1988-09-28
AU1375688A (en) 1988-09-29
EP0284407B1 (en) 1991-05-29
DK164388D0 (da) 1988-03-25
PT87081A (pt) 1988-04-01
JP2719344B2 (ja) 1998-02-25
CA1308026C (en) 1992-09-29
PT87081B (pt) 1992-07-31
ZA882168B (en) 1989-11-29
KR960013434B1 (ko) 1996-10-05
IE60605B1 (en) 1994-07-27
IL85870A (en) 1992-02-16
ATE63818T1 (de) 1991-06-15
NZ224026A (en) 1991-03-26
JPS63255230A (ja) 1988-10-21
AU607474B2 (en) 1991-03-07
EP0284407A3 (en) 1988-12-14
US4917900A (en) 1990-04-17
GR3002030T3 (en) 1992-12-30
DE3862974D1 (de) 1991-07-04
DK164388A (da) 1988-09-28
GB8707421D0 (en) 1987-04-29

Similar Documents

Publication Publication Date Title
ES2033426T3 (es) Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina.
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2099145T3 (es) Heparosanos n,o-sulfatados, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
GR1000392B (el) Σταθεροποιημενες συνθεσεις περιεχουσες επιδερμικο παραγοντα αναπτυξης.
ES2059377T3 (es) Pirazoles 1,5-diaril-3-sustituidos farmacologicamente activos y procedimiento para sintetizar los mismos.
ES2185711T3 (es) 1,4-benzotiazepina-1,1-dioxidoshipolipimemicos.
MX9204354A (es) Compuestos heterociclicos de 5 miembros, procedimiento para prepararlos y composiciones farmaceuticas que los contienen.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES2061559T3 (es) Triazolinonas substituidas.
ES502080A0 (es) Procedimiento para la preparacion de composiciones fosfoli- pidicas de colina
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9401295A (es) Fosfonatos sustituidos, los procedimientos para supreparacion y composiciones farmaceuticas que los contienen.
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2122221T3 (es) Compuestos terapeuticos adecuados para el tratamiento de enfermedades conectadas con la deficiencia de glutation, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2052622T3 (es) Derivados de benzodioxol, compuestos que los comprenden y utilizacion de los mismos para la fabricacion de medicamentos.
MX6274E (es) Procedimiento para la preparacion de composiciones parmaceuticas que contienen alcohilantes citostaticos destoxificados
MX9304676A (es) Liponucleosidos de seco-nucleosidos, procedimiento para su preparacion y composiciones con actividad antiviral que los contienen.
MX9302429A (es) Nuevas tetralonas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
ES2039284T3 (es) Un procedimiento para preparar derivados de la 1-benzoil-2-oxo-5-alcoxi-pirrolidina.
ES2158309T3 (es) Fenilamidinas sustituidas, medicamentos que contienen a estos compuestos y procedimiento para su preparacion.
ES2054029T3 (es) Formulacion de acetato de flecainida con liberacion controlada.
ES2172172T3 (es) Composiciones farmaceuticas solidas para la administracion por via oral que permiten la liberacion modulada de nicorandil y su procedimiento de preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 284407

Country of ref document: ES